|
|
Paragon 28 inc (NYSE: FNA) |
|
Price: $12.9900
$0.00 
0.000%
|
| Day's High:
| $13.02
| Week Perf:
| 0.00
|
| Day's Low: |
$ 12.98 |
30 Day Perf: |
-0.15 % |
| Volume (M): |
1,831,300 |
52 Wk High: |
$ 0.00 |
| Volume (M$): |
$ 23,789 |
52 Wk Avg: |
$0.00 |
| Open: |
$13.00 |
52 Wk Low: |
$0.00 |
|
|
| Market Capitalization (Millions $) |
1,082 |
| Shares
Outstanding (Millions) |
83 |
| Employees |
144 |
| Revenues (TTM) (Millions $) |
255 |
| Net Income (TTM) (Millions $) |
-55 |
| Cash Flow (TTM) (Millions $) |
-41 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
The company is a leading medical device company that is exclusively focused on the foot and ankle orthopedic market. They are dedicated to improving patient lives and providing innovative orthopedic solutions, procedural approaches, and instrumentation for a wide range of foot and ankle ailments. The company's comprehensive portfolio of solutions includes surgical implants and disposables, as well as surgical instrumentation. Their products are designed with both the patient and surgeon in mind to improve outcomes, reduce ailment recurrence and complication rates, and make the procedures simpler, consistent, and reproducible.
The global market for surgical implants and devices used in foot and ankle procedures is projected to grow at approximately 7% annually to reach approximately $6.0 billion by 2026, representing the fastest growing market within orthopedics. The company believes that growth in the foot and ankle market could accelerate with an increased focus on specialization and with advancements in technology that improve patient outcomes.
The foot and ankle market is dominated by a handful of incumbents that operate across the broader medical device and orthopedic markets. The company believes that slow technological and procedural advancement in this market is resulting from a lack of exclusive focus on the foot and ankle market, limited clinical education, understanding and consistent techniques for treating foot and ankle conditions, lack of specialized and clinically focused sales forces, lack of patient specific solutions, lack of advanced technologies, and lack of unbiased research.
To disrupt and transform the market, the company focuses exclusively on the foot and ankle market to develop and commercialize differentiated, high-quality orthopedic solutions, advanced procedural approaches, and instrumentation. Their development strategy integrates all aspects of the procedure, including enhancing support systems beyond implants. They rely on an unbiased, clinical, research-first approach to developing new products and each of their systems is designed to deliver an enhanced user-experience throughout the procedure while improving patient outcomes and increasing the reproducibility of results. They deliver their products through a clinically focused sales force and dedicate themselves to medical education to support surgeons, patients, and stakeholders within their organization.
The company has developed a comprehensive portfolio of foot and ankle surgical systems and procedural techniques designed to address many of the conditions requiring surgery in the foot and ankle. Each system typically includes numerous plates, screws, staples, nails, advanced joint and bone replacements, orthobiologics, and other implantation instruments and disposables. They have designed and currently market 75 product systems with approximately 9,200 SKUs, which comprises of approximately 6,800 implants, 1,400 instruments and 1,000 disposable and other SKUs.
The company has introduced numerous key technological innovations and novel products that have advanced and challenged the status quo in their industry. They are committed to continuously expanding and advancing their portfolio of foot and ankle surgical solutions and bringing next-generation products to market.
In addition to their portfolio of products, the company uses Smart 28 to modernize and improve all aspects of foot and ankle treatments by utilizing advanced technologies such as AI, data analytics, patient-specific algorithms, 3-D modeling, and other enabling technologies. Smart 28 aims to further improve patient outcomes and procedure reproducibility, as well as increased patient access to therapies.
Company Address: 14445 Grasslands Drive Englewood 80112 CO
Company Phone Number: 912-1332 Stock Exchange / Ticker: NYSE FNA
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Announcement
Published Tue, Mar 25 2025 4:21 PM UTC
Paragon 28, Inc. (NYSE: FNA), a company specializing in innovative surgical solutions for foot and ankle care, is under the spotlight as Kaskela Law LLC has announced an investigation into its proposed stockholder buyout. This development comes at a time when the company s stock is valued at approximately $13.015, with an estimated 82.79 million shares outstanding. As invest...
|
| Business Update
Published Sat, Jan 4 2025 2:58 AM UTC
Stepping Into the Spotlight: Paragon 28 Debuts on the J.P. Morgan Stage In the ever-evolving landscape of medical technology, Paragon 28, Inc. has carved a niche as a front-runner in the foot and ankle orthopaedic market. The Colorado-based company, listed on the New York Stock Exchange under the ticker FNA, is poised to present at the prestigious 43rd Annual J.P. Morgan Hea...
|
| Business Update
Published Fri, Jan 3 2025 5:18 PM UTC
Paragon 28 to Showcase Innovations and Leadership at the 43rd Annual J.P. Morgan Healthcare Conference ENGLEWOOD, Colo. Paragon 28, Inc. (NYSE: FNA), a prominent figure in the medical device sector focusing solely on foot and ankle orthopedic solutions, is set to present at the illustrious 43rd Annual J.P. Morgan Healthcare Conference. The event will take place on Monday, ...
|
| Announcement
Published Thu, Nov 21 2024 6:19 PM UTC
In a pivotal announcement that has significant implications for shareholders, Levi & Korsinsky, LLP has reminded investors of an impending lead plaintiff deadline for a class action lawsuit involving Paragon 28, Inc. (NYSE: FNA). The deadline is set for November 29, 2024 , and all shareholders who believe they were adversely affected by the company s actions are urged to ...
|
| Business Update
Published Wed, Oct 16 2024 9:36 PM UTC
Paragon 28, Inc. (NYSE: FNA) has announced the launch of its latest product, the Phantom Fibula Nail System, a less invasive surgical solution for treating ankle fractures. This cutting-edge system is designed to provide orthopedic surgeons with an alternative to traditional plate and screw fixation, now recognized as a common technique for repairing fibular injuries.The Pha...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-0.66 $ |
| Revenues (TTM) |
3.07 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.42 $
|
| Book Value |
1.57 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
1,774,229 |
| Net
Income per Employee (TTM) |
-379,437 |
| Receivable Turnover Ratio (TTM) |
6.76 |
| Inventory Turnover Ratio (TTM) |
0.68 |
| Asset Turnover Ratio (TTM) |
0.83 |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.66 $
|
| Revenues (TTM) |
3.07 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.42 $
|
| Book Value |
1.57 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
On November 13 2024 the Paragon 28 Inc provided following guidance
Paragon 28 Inc. has recently revised its financial projections for the year 2024, as detailed in their report dated November 13, 2024. This update follows the company's announcement of its third quarter financial results, which reflects a robust performance and an optimistic outlook for the remainder of the year.
In their latest updates, Paragon 28 disclosed its net revenues for the quarter ending September 30, 2024, which totaled $62.3 million. This figure represents a significant year-over-year increase, reflecting an 18.1% rise in reported revenue and a commendable 17.6% increase when adjusted for constant currency fluctuations. Such growth underscores Paragon 28’s strong position within the fo...
|
|
|
0.28% 